Hematology-Oncology

Research

Overview

Faculty and fellows of the Division of Pediatric Hematology-Oncology are engaged in a wide range of clinical, translational and basic investigation related to pediatric cancer, disorders of the blood including clotting or bleeding problems, and the quality of life of children and their families undergoing severe medical conditions.

Research Faculty

Name	Areas of Special Interest
Daniel Wechsler, MD, PhD	Understanding the role of aberrant proteins in the development of childhood leukemia, as well as characterization of novel proteins involved in neuroblastoma in order to generate more targeted therapy.
Susan Kreissman, MD	Improving the treatment of neuroblastoma through the study of new treatment plans, coordinating multidisciplinary care for retinoblastoma patients, leading national inquiry in COG neuroblastoma treatment studies.
Philip Rosoff, MD	Clinical ethics and medical decision making, as well as improving the psychosocial/physiologic functioning of long-term survivors of cancer. Moral implications of behavioral genetics and genetic determinism.
Raymond Barfield, MD	Study of the intersection of medicine, theology, philosophy, and literature in an attempt to improve the quality of life of children and their families experiencing severe medical illness.
Cassandra Moran, DO	Pharmacokinetics, safety, and efficacy of therapeutic agents used in children. Pediatric clinical trials, including industry and investigator-initiated clinical studies. Design and development of studies critical for the labeling of drugs in children.
Corinne Linardic, MD, PhD	The study of childhood rhabdomyosarcoma, using primary cell-based and xenograft models to understand the implicated signaling pathways and to identify potential therapeutic targets.
Courtney Thornburg, MD	Clinical trials and health services research related to pediatric hemostasis and thrombosis, ITP, and sickle cell disease.
Michael Armstrong, MD, PhD	Understanding the physiology of neuroblastoma and specific chemotherapy effects in order to develop more targeted therapies as well as participating in clinical studies aimed at applying recent scientific discoveries in order to improve the outcomes of children with neuroblastoma.
Eugene Hwang, MD	Indentification and evaluation of targeted molecular therapeutics for solid tumors in general, and medulloblastoma in specific.